CARsgen Therapeutics (HKG:2171), a leading CAR T-cell therapy developer, saw its stock price surge 5.10% in intraday trading on Friday following the release of its impressive 2025 interim results. The company reported significant progress in its product pipeline and a substantial improvement in its financial performance, attracting investor interest.

The Hong Kong-listed biotech firm announced a dramatic increase in revenue, jumping to 51 million yuan in the first half of 2025 from 6.3 million yuan in the same period last year. This eightfold increase was primarily driven by the sales of zevor-cel, its approved CAR T-cell therapy for multiple myeloma. Additionally, CARsgen's losses narrowed considerably, with attributable loss decreasing to 75.5 million yuan from 351.6 million yuan year-over-year, signaling improved operational efficiency.

Investors were also encouraged by CARsgen's advancements in its product pipeline. Notably, the company's satri-cel became the world's first CAR T-cell product to file a New Drug Application for the treatment of solid tumors, specifically for gastric cancer. Furthermore, CARsgen reported progress in multiple allogeneic CAR-T products under development, covering various treatment areas including hematologic malignancies, solid tumors, and autoimmune diseases. The company's strong cash position, with expected cash and cash equivalents of not less than 1,100 million yuan by the end of 2025, provides confidence in its ability to fund ongoing research and development efforts through 2028.